VolitionRx Limited (NYSEAMERICAN:VNRX) Sees Significant Growth in Short Interest

VolitionRx Limited (NYSEAMERICAN:VNRX) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 546,400 shares, an increase of 23.6% from the October 31st total of 441,900 shares. Based on an average trading volume of 123,400 shares, the short-interest ratio is presently 4.4 days.

VolitionRx Price Performance

Shares of VolitionRx stock traded down $0.04 during trading hours on Monday, reaching $0.65. The stock had a trading volume of 385,188 shares, compared to its average volume of 163,437. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The company has a market cap of $41.04 million, a price-to-earnings ratio of -1.16 and a beta of 1.59.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.